Transgene Biotek (526139.BO) Stock Price
Transgene Biotek Price
Revenue at Transgene Biotek has contracted by 11.2% per year over the past 19 years to 2.11 M INR. Earnings per share have grown at 16.4% per year over the last 5 years. For Transgene Biotek, the net margin of -782.6% is up versus -11,998.4% a few years ago.
Transgene Biotek stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Transgene Biotek business model & stock analysis
Frequently asked questions about Transgene Biotek
Converted at the current exchange rate, the Transgene Biotek share trades at 0.02 EUR (2.49 INR).
The revenue of Transgene Biotek is 2.11 M INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Transgene Biotek is -16.53 M INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Transgene Biotek is currently -11.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Transgene Biotek stock.
The price-to-sales ratio (P/S) of Transgene Biotek is currently 89.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Transgene Biotek stock.
The Eulerpool Quality Score for Transgene Biotek is 3/10.
The ISIN of Transgene Biotek is INE773D01018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Transgene Biotek is 526139.BO. The ticker symbol is used to trade Transgene Biotek shares on the stock exchange.
Transgene Biotek stock
Transgene Biotek Peer Group
Transgene Biotek FIGI
All fundamentals and in-depth analysis of Transgene Biotek
Our stock analysis for Transgene Biotek stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Transgene Biotek. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.